Drug intelligence / Profile preview

320Eu

Development stage: Preclinical
Lead developer: AIM Vaccine Co.
Modality: Vaccines & Immunotherapeutics

Overview

320Eu refers to a specific dosage (320 EU, likely ELISA Units) of an Enterovirus type 71 (EV71) inactivated vaccine. This vaccine is designed to induce an immune response against EV71 infection. In studies involving neonatal rhesus monkeys, immunization with the 320EU dose induced a mild immune response, characterized by varying Th1/Th2 reactions and T-cell cytotoxicity, compared to other dosages. Clinical trials for the EV71 inactivated vaccine are progressing, aiming to prevent EV71 infection.

Beyond the preview

Go deeper on 320Eu.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 320Eu.

Explore the full profile